IRCT20140818018842N23 IRCT 2022-04-03 Tehran University of Medical Sciences Evaluation of the Pastocovac (COVID-19 vaccine) efficacy following autologous stem cell transplantation ESVَََAHSCT Evaluation of SARS-CoV-۲ Vaccine (Pastocovac) effectiveness and serologic response in Patients Receiving Hematopoietic Autologous Stem Cell Transplantation compared to control group: A clinical trial 2022-04-03 anticipated 124 Complete https://irct.ir/trial/62549 interventional Randomization: Not randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Prevention. 2 Condition 1: Autologous stem cell transplantation. Condition 2: SARS-CoV-2 vaccine efficacy. Intervention 1: Intervention group: All patients who underwent autologous SCT and have inclusion criteria will be enrolled and will receive the first dose of pastocovac from 3 months post-transplant. The second dose will receive at four weeks (±7 days) interval of the first dose and the booster will receive at four weeks (±7 days) interval of the second dose. The serologic responses will be assessed by measurement of SARS-CoV-2 specific IgG (anti-S1) before the first vaccine, before the second vaccine, four weeks after the second vaccine, and six months after the first vaccine. Intervention 2: Control group: The control group includes healthy people who have received two doses of Pastococcal vaccine with the same formula and dose as the intervention group, and the antibody titer is measured before and after each dose of the vaccine. No - There is not a plan to make this available Justification or reason for not sharing IPD is There is no further information"